A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) With Persistent Asthma
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society.
- 13 Nov 2007 Status changed from recruiting to completed
- 25 Nov 2006 New trial record.